A detailed history of Royal Bank Of Canada transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 22,099 shares of SAGE stock, worth $154,472. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,099
Previous 17,827 23.96%
Holding current value
$154,472
Previous $334,000 28.44%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$10.58 - $17.9 $45,197 - $76,468
4,272 Added 23.96%
22,099 $239,000
Q1 2024

May 15, 2024

SELL
$18.62 - $26.95 $254,107 - $367,786
-13,647 Reduced 43.36%
17,827 $334,000
Q4 2023

Feb 14, 2024

SELL
$17.1 - $22.26 $105,096 - $136,809
-6,146 Reduced 16.34%
31,474 $682,000
Q3 2023

Nov 14, 2023

BUY
$16.75 - $48.98 $365,954 - $1.07 Million
21,848 Added 138.52%
37,620 $774,000
Q2 2023

Aug 14, 2023

BUY
$40.65 - $59.54 $37,316 - $54,657
918 Added 6.18%
15,772 $741,000
Q1 2023

May 15, 2023

SELL
$37.27 - $46.57 $108,343 - $135,378
-2,907 Reduced 16.37%
14,854 $623,000
Q4 2022

Feb 14, 2023

BUY
$32.2 - $43.61 $221,664 - $300,211
6,884 Added 63.29%
17,761 $677,000
Q3 2022

Nov 14, 2022

SELL
$32.28 - $43.27 $149,133 - $199,907
-4,620 Reduced 29.81%
10,877 $426,000
Q2 2022

Aug 15, 2022

SELL
$27.52 - $37.99 $107,905 - $148,958
-3,921 Reduced 20.19%
15,497 $500,000
Q1 2022

May 16, 2022

SELL
$30.71 - $45.71 $258,455 - $384,695
-8,416 Reduced 30.24%
19,418 $643,000
Q4 2021

Feb 14, 2022

BUY
$37.06 - $47.11 $212,353 - $269,940
5,730 Added 25.92%
27,834 $1.18 Million
Q3 2021

Nov 15, 2021

SELL
$40.26 - $57.37 $1.95 Million - $2.77 Million
-48,342 Reduced 68.62%
22,104 $979,000
Q2 2021

Aug 16, 2021

BUY
$54.88 - $79.29 $3.87 Million - $5.59 Million
70,446 New
70,446 $4 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $415M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.